

# Catabasis Update

## Phase 3 PolarisDMD Trial for Edasalonexent in Duchenne is Open for Enrollment in Australia!

**The Royal Children's Hospital Melbourne is enrolling boys in the Phase 3 PolarisDMD clinical trial of edasalonexent in Duchenne muscular dystrophy.**

Sites in South Brisbane, Queensland and Sydney, New South Wales are expected to be open for enrollment soon! PolarisDMD is enrolling boys ages 4 to 7 (up to 8th birthday), regardless of mutation type, who have not been on steroids for at least 6 months.

PolarisDMD is a 1-year trial, and is open to families across Australia and New Zealand. Travel accommodation can be arranged for those who need it.

Interested families in Australia and New Zealand can visit our [website](#) and email [DMDtrials@Catabasis.com](mailto:DMDtrials@Catabasis.com) for more information.

### About edasalonexent (CAT-1004)

Edasalonexent inhibits NF- $\kappa$ B, a protein which plays a fundamental role in skeletal and cardiac muscle disease in DMD. By inhibiting NF- $\kappa$ B, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression.



**PolarisDMD in Australia**

- Expected Site
- Recently Activated Site

- Age 4-7 (up to 8th birthday)
- Not on steroids for at least 6 months
- Any mutation type

### Stay in touch!

Join our mailing list: <http://www.catabasis.com/patients-families/for-further-information.php>  
Follow @CatabasisPharma on [Facebook](#), [Twitter](#), and [Instagram](#)  
Ask a question about the trial: [DMDtrials@catabasis.com](mailto:DMDtrials@catabasis.com)  
For more information about sites, please visit: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)